Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab vs Enoxaparin in TKA
NCT03393481Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of abelacimab in venous thromboembolism (VTE) (3 arms), sponsored by Novartis. Primary endpoint: Number of patients with confirmed composite endpoint at Day 14. Planned start Oct 2018; status: withdrawn.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03393481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393481.